Annual EBITDA
-$21.88 M
+$9.73 M+30.78%
December 31, 2023
Summary
- As of February 12, 2025, CRDL annual EBITDA is -$21.88 million, with the most recent change of +$9.73 million (+30.78%) on December 31, 2023.
- During the last 3 years, CRDL annual EBITDA has fallen by -$6.60 million (-43.25%).
- CRDL annual EBITDA is now -1732.55% below its all-time high of -$1.19 million, reached on December 1, 2017.
Performance
CRDL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$10.21 M
-$4.60 M-82.05%
September 30, 2024
Summary
- As of February 12, 2025, CRDL quarterly EBITDA is -$10.21 million, with the most recent change of -$4.60 million (-82.05%) on September 30, 2024.
- Over the past year, CRDL quarterly EBITDA has dropped by -$4.60 million (-82.05%).
- CRDL quarterly EBITDA is now -2472.30% below its all-time high of -$397.10 thousand, reached on September 1, 2017.
Performance
CRDL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$27.86 M
-$4.56 M-19.56%
September 30, 2024
Summary
- As of February 12, 2025, CRDL TTM EBITDA is -$27.86 million, with the most recent change of -$4.56 million (-19.56%) on September 30, 2024.
- Over the past year, CRDL TTM EBITDA has dropped by -$4.56 million (-19.56%).
- CRDL TTM EBITDA is now -6916.02% below its all-time high of -$397.10 thousand, reached on September 1, 2017.
Performance
CRDL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CRDL EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +30.8% | -82.0% | -19.6% |
| 3 y3 years | -43.3% | -82.0% | -19.6% |
| 5 y5 years | -87.3% | -82.0% | -19.6% |
CRDL EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +30.8% | -119.6% | +1.3% | -27.4% | +21.1% |
| 5 y | 5-year | -114.5% | +30.8% | -353.4% | +1.3% | -187.6% | +21.1% |
| alltime | all time | -1732.5% | +30.8% | -2472.3% | +1.3% | -6916.0% | +21.1% |
Cardiol Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$10.21 M(+82.0%) | -$27.86 M(+19.6%) |
| Jun 2024 | - | -$5.61 M(-9.3%) | -$23.30 M(+4.3%) |
| Mar 2024 | - | -$6.19 M(+5.8%) | -$22.34 M(+2.2%) |
| Dec 2023 | -$21.88 M(-30.8%) | -$5.85 M(+3.4%) | -$21.87 M(-3.5%) |
| Sep 2023 | - | -$5.66 M(+21.6%) | -$22.67 M(-16.3%) |
| Jun 2023 | - | -$4.65 M(-18.6%) | -$27.10 M(-8.5%) |
| Mar 2023 | - | -$5.71 M(-14.2%) | -$29.63 M(-6.2%) |
| Dec 2022 | -$31.60 M(+3.1%) | -$6.65 M(-34.0%) | -$31.60 M(-10.5%) |
| Sep 2022 | - | -$10.08 M(+40.4%) | -$35.29 M(+6.2%) |
| Jun 2022 | - | -$7.18 M(-6.5%) | -$33.24 M(+6.4%) |
| Mar 2022 | - | -$7.68 M(-25.8%) | -$31.24 M(+2.1%) |
| Dec 2021 | -$30.66 M | - | - |
| Dec 2021 | - | -$10.35 M(+28.9%) | -$30.60 M(+10.9%) |
| Sep 2021 | - | -$8.03 M(+54.8%) | -$27.59 M(+20.8%) |
| Jun 2021 | - | -$5.19 M(-26.4%) | -$22.83 M(+13.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$7.04 M(-4.0%) | -$20.19 M(+31.1%) |
| Dec 2020 | -$15.27 M(+49.8%) | -$7.34 M(+124.6%) | -$15.40 M(+48.9%) |
| Sep 2020 | - | -$3.27 M(+28.4%) | -$10.34 M(+6.7%) |
| Jun 2020 | - | -$2.54 M(+12.9%) | -$9.69 M(-1.5%) |
| Mar 2020 | - | -$2.25 M(-1.1%) | -$9.84 M(-3.5%) |
| Dec 2019 | -$10.20 M(-12.7%) | -$2.28 M(-12.8%) | -$10.19 M(-30.0%) |
| Sep 2019 | - | -$2.61 M(-3.0%) | -$14.55 M(-5.9%) |
| Jun 2019 | - | -$2.69 M(+3.4%) | -$15.47 M(+12.7%) |
| Mar 2019 | - | -$2.61 M(-60.7%) | -$13.73 M(+19.1%) |
| Dec 2018 | -$11.68 M(+878.6%) | -$6.64 M(+87.9%) | -$11.53 M(+116.7%) |
| Sep 2018 | - | -$3.53 M(+271.4%) | -$5.32 M(+143.6%) |
| Jun 2018 | - | -$951.40 K(+135.4%) | -$2.18 M(+77.2%) |
| Mar 2018 | - | -$404.20 K(-6.2%) | -$1.23 M(+48.8%) |
| Dec 2017 | -$1.19 M | -$431.00 K(+8.5%) | -$828.10 K(+108.5%) |
| Sep 2017 | - | -$397.10 K | -$397.10 K |
FAQ
- What is Cardiol Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Cardiol Therapeutics?
- What is Cardiol Therapeutics annual EBITDA year-on-year change?
- What is Cardiol Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Cardiol Therapeutics?
- What is Cardiol Therapeutics quarterly EBITDA year-on-year change?
- What is Cardiol Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Cardiol Therapeutics?
- What is Cardiol Therapeutics TTM EBITDA year-on-year change?
What is Cardiol Therapeutics annual EBITDA?
The current annual EBITDA of CRDL is -$21.88 M
What is the all time high annual EBITDA for Cardiol Therapeutics?
Cardiol Therapeutics all-time high annual EBITDA is -$1.19 M
What is Cardiol Therapeutics annual EBITDA year-on-year change?
Over the past year, CRDL annual EBITDA has changed by +$9.73 M (+30.78%)
What is Cardiol Therapeutics quarterly EBITDA?
The current quarterly EBITDA of CRDL is -$10.21 M
What is the all time high quarterly EBITDA for Cardiol Therapeutics?
Cardiol Therapeutics all-time high quarterly EBITDA is -$397.10 K
What is Cardiol Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CRDL quarterly EBITDA has changed by -$4.60 M (-82.05%)
What is Cardiol Therapeutics TTM EBITDA?
The current TTM EBITDA of CRDL is -$27.86 M
What is the all time high TTM EBITDA for Cardiol Therapeutics?
Cardiol Therapeutics all-time high TTM EBITDA is -$397.10 K
What is Cardiol Therapeutics TTM EBITDA year-on-year change?
Over the past year, CRDL TTM EBITDA has changed by -$4.56 M (-19.56%)